Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories… Read more
Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) - Total Assets
Latest total assets as of September 2025: €452.04 Million EUR
Based on the latest financial reports, Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) holds total assets worth €452.04 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eckert & Ziegler Strahlen- und Medizintechnik AG - Total Assets Trend (2013–2024)
This chart illustrates how Eckert & Ziegler Strahlen- und Medizintechnik AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Eckert & Ziegler Strahlen- und Medizintechnik AG - Asset Composition Analysis
Current Asset Composition (December 2024)
Eckert & Ziegler Strahlen- und Medizintechnik AG's total assets of €452.04 Million consist of 50.9% current assets and 49.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 26.7% |
| Accounts Receivable | €43.22 Million | 9.8% |
| Inventory | €43.92 Million | 9.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €12.65 Million | 2.9% |
| Goodwill | €36.97 Million | 8.4% |
Asset Composition Trend (2013–2024)
This chart illustrates how Eckert & Ziegler Strahlen- und Medizintechnik AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eckert & Ziegler Strahlen- und Medizintechnik AG's current assets represent 50.9% of total assets in 2024, an increase from 40.7% in 2013.
- Cash Position: Cash and equivalents constituted 26.7% of total assets in 2024, up from 16.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 28.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 9.9% of total assets.
Eckert & Ziegler Strahlen- und Medizintechnik AG Competitors by Total Assets
Key competitors of Eckert & Ziegler Strahlen- und Medizintechnik AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Eckert & Ziegler Strahlen- und Medizintechnik AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Eckert & Ziegler Strahlen- und Medizintechnik AG generates 0.67x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Eckert & Ziegler Strahlen- und Medizintechnik AG generates $7.52 in net profit.
Eckert & Ziegler Strahlen- und Medizintechnik AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.93 | 2.77 | 3.52 |
| Quick Ratio | 2.37 | 2.32 | 2.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €161.06 Million | € 177.31 Million | € 123.72 Million |
Eckert & Ziegler Strahlen- und Medizintechnik AG - Advanced Valuation Insights
This section examines the relationship between Eckert & Ziegler Strahlen- und Medizintechnik AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.96 |
| Latest Market Cap to Assets Ratio | 1.38 |
| Asset Growth Rate (YoY) | 0.7% |
| Total Assets | €442.40 Million |
| Market Capitalization | $610.05 Million USD |
Valuation Analysis
Above Book Valuation: The market values Eckert & Ziegler Strahlen- und Medizintechnik AG's assets above their book value (1.38 x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Eckert & Ziegler Strahlen- und Medizintechnik AG's assets grew by 0.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Eckert & Ziegler Strahlen- und Medizintechnik AG (2013–2024)
The table below shows the annual total assets of Eckert & Ziegler Strahlen- und Medizintechnik AG from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €442.40 Million | +0.69% |
| 2023-12-31 | €439.36 Million | +5.40% |
| 2022-12-31 | €416.84 Million | +19.87% |
| 2021-12-31 | €347.73 Million | +19.08% |
| 2020-12-31 | €292.00 Million | +6.48% |
| 2019-12-31 | €274.24 Million | +19.73% |
| 2018-12-31 | €229.05 Million | +5.56% |
| 2017-12-31 | €216.99 Million | +8.78% |
| 2016-12-31 | €199.47 Million | +1.42% |
| 2015-12-31 | €196.68 Million | +4.99% |
| 2014-12-31 | €187.33 Million | +5.00% |
| 2013-12-31 | €178.41 Million | -- |